Artelo Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTL research report →
Price Chart
About the company
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.
- CEO
- Gregory D. Gorgas
- IPO
- 2019
- Employees
- 7
- HQ
- Solana Beach, CA, US
Get TickerSpark's AI analysis on ARTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.84M
- P/E
- -0.02
- Fwd P/E
- 0.01
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.12
- EV/EBITDA
- -0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -272.21%
- ROIC
- -155.70%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,404,000
- Net Income
- $-12,879,000-31.1%
- EPS
- $-49.23-438.1%
- OCF Growth
- -2.0%
- FCF Growth
- -2.0%
- 52W High
- $179.19
- 52W Low
- $1.30
- 50D MA
- $3.04
- 200D MA
- $18.54
- Beta
- -0.07
- RSI (14)
- 25
- Avg Volume
- 476.69K
No earnings-call transcripts are available for ARTL yet.
- Free Float
- 62.4%
- Shares Outstanding
- 3.49M
- Float Shares
- 241.50K
of shares held by institutions
10 13F filers
Buy/sell ratio 0.72. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 14.03K | 0 |
| Ubs Group AG | 13.02K | ▲ 10.21K |
| Jane Street Group, LLC | 12.03K | ▼ 54.31K |
| Tower Research Capital LLC (Trc) | 8.44K | ▲ 5.61K |
| Citigroup Inc | 3.57K | ▲ 3.57K |
| Vanguard Capital Management LLC | 1.13K | ▼ 9.00K |
| Vanguard Fiduciary Trust Co | 350 | ▼ 2.79K |
| Altshuler Shaham Ltd | 111 | ▲ 111 |
| Rothschild Investment LLC | 2 | 0 |
| Cwm, LLC | 1 | ▲ 1 |
Held by 5 ETFs
Biggest fund positions in ARTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 17, 26 | MATSUI CONNIE | other | 136 |
| Jul 17, 26 | Blayney Douglas | other | 136 |
| Jul 17, 26 | Reyes Gregory | other | 136 |
| Jul 17, 26 | EMANUELE ROBERT MARTIN | other | 136 |
| Jul 17, 26 | Kelly Steven | other | 136 |
| Jul 17, 26 | FAVORITO TAMARA A | other | 136 |
| Jan 30, 26 | MATSUI CONNIE | other | 292 |
| Jan 30, 26 | Blayney Douglas | other | 292 |
| Jan 30, 26 | EMANUELE ROBERT MARTIN | other | 292 |
| Jan 30, 26 | Kelly Steven | other | 292 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARTL coverage
Recent articles, reports, and earnings notes.
No research on ARTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARTL report →Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
globenewswire.com · Nov 12
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
globenewswire.com · Oct 29
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
globenewswire.com · Oct 26
Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Rises 104.7%
defenseworld.net · Oct 16
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
globenewswire.com · Oct 7
Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in September
defenseworld.net · Oct 1
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
globenewswire.com · Sep 23
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
globenewswire.com · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.